Historical Parallels

Watch your back.

Send me real-time posts from this site at my email
Wendy Boyd

RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data

Following the 90-percent year-to-date appreciation in Intercept Pharmaceutical, Inc. ICPT shares, RBC Capital Markets considers the stock's risk-reward to be balanced. 

RBC Capital Markets analyst Brian Abrahams downgraded Intercept from Outperform to Sector Perform with a $115 price target. Source

Seems like downside will take some place due to stochastics head south. 

$ICPT, INTERCEPT PHARMACEUTICALS IN / D